O-3 - Advances in Time to Test Results in the Bacteriology Lab

Co-Author(s)

• CA

  Cesar Arias, M.D., MSc, Ph.D., FIDSA

  Professor
  Internal Medicine
  CARMiG, UTHealth and Center for Infectious Diseases, UTHealth School of Public Health, HOU, TX ; Molecular Genetics and Antimicrobial Resistance Unit and International Center for Microbial Genomics, Universidad El Bosque, BOG, COL
  Houston, Texas

  Disclosure: Entasis Therapeutics : Scientific Research Study Investigator; MeMed : Scientific Research Study Investigator; Merck : Grant/Research Support
• MB

  Micah Bhatti, MD, PhD

  Assistant Professor
  Department of Laboratory Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• RB

  Robert Birch, n/a

  PhD
  Data Analytics
  Biomérieux
  Hazelwood, Missouri

  Disclosure: bioMerieux Inc. (Employee)
• RC

  Rafael Cantón, PharmD PhD

  PharmD PhD
  Clinical Microbiology
  Hospital Ramón y Cajal
  Madrid, Madrid, Spain

  Disclosure: Biomérieux (Grant/Research Support)
• JC

  José Luis Cortés Cuevas, MD

  MD
  Clinical Microbiology
  Hospital Ramón y Cajal
  Madrid, Madrid, Spain

  Disclosure: biomerieux (Research Grant or Support)biomerieux (Research Grant or Support)
• MC

  Miriam Cuesta, n/a

  Technician
  Clinical Microbiology
  Hospital Ramón y Cajal
  Madrid, Madrid, Spain

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• JD

  Juan Antonio Del Castillo Polo, MD

  MD
  Clinical Microbiology
  Hospital Ramón y Cajal
  Madrid, Madrid, Spain

  Disclosure: Biomérieux (Research Grant or Support)
• SE

  Samuel Erickson, BS

  Medical Student
  McGovern Medical School
  Houston, Texas

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• GG

  Gerard Gawrys, PharmD, BCPS, BCIDP

  Infectious Diseases Pharmacist
  Methodist Hospital & Methodist Children's Hospital
  San Antonio, Texas

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• WG

  Will Godinez, B.S., PharmD

  PharmD
  University of Texas at Austin College of Pharmacy
  San Antonio, Texas

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• HH

  Holly Huse, PhD. D(ABMM)

  Clinical Microbiology Manager
  Microbiology Department
  Huntington Hospital
  Pasadena, California

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• CJ

  Christopher Jackson, PharmD

  PharmD
  University of Texas at Austin College of Pharmacy
  San Antonio, Texas

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• 

  Joseph Kuti, PharmD

  Associate Director, Clinical and Economic Studies
  Center for Anti-Infective Research and Development, Hartford Hospital
  Hartford, Connecticut

  Disclosure: Allergan : Speakers' bureau; bioMérieux : Other Financial or Material Support, Research Grant or Support, Speaker Honorarium; Melinta : Research Grant or Support; Merck & Co., Inc. : Research Grant or Support; Paratek : Speakers' bureau; Summit : Other Financial or Material Support, Research funding (clinical trials); Tetraphase : Speakers' bureau (Status: Ongoing)
• GL

  Grace Lee, PharmD, PhD, BCPS

  Assistant Professor
  Pharmacotherapy Division
  The University of Texas at Austin College of Pharmacy, Pharmacotherapy Education and Research Center, School of Medicine, UT Health San Antonio
  San Antonio, Texas

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• TL

  Todd Lee, MD, MPH

  Associate Professor of Medicine
  Medicine
  McGill University
  Montreal, Quebec, Canada

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• BL

  Brigitte Lefebvre, PhD

  Spécialiste clinique en Biologie Médicale
  Institut National de Santé Publique du Québec
  Montreal, Quebec, Canada

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• GL

  Gleice Leite, PhD

  Research Associate
  McGill University Health Centre
  Montreal, Quebec, Canada

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• JL

  Jean Longtin, MD

  Medical Microbiologist
  Centre de Recherce en Infectiologie
  Université Laval
  Montreal, Quebec, Canada

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• 

  William Miller, MD

  Assistant Professor
  UTHealth McGovern Medical School
  Houston, Texas

  Disclosure: Entasis () : Grant/Research Support; Merck () : Grant/Research Support; Shionogi () : Advisory Board
• DN

  David Nicolau, PharmD

  Director
  Center for Anti-Infective Research and Development
  Hartford Hospital
  Hartford, Connecticut

  Disclosure: Cepheid (Other Financial or Material Support, Consultant, speaker bureau member or has received research support .)Merck & Co., Inc. (Consultant, Grant/Research Support, Speaker's Bureau)Wockhardt (Grant/Research Support)
• CP

  Cedric Pettaway, Jr., BS

  Research Assistant
  McGovern Medical School
  Houston, Texas

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• AS

  Ana María Sánchez Díaz, PharmD. PhD.

  PharmD PhD
  Clinical Microbiology
  Hospital Ramón y Cajal
  Madrid, Madrid, Spain

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• ST

  Sergio Talens, n/a

  Biologist
  Clinical Microbiology
  Hospital Ramón y Cajal
  Madrid, Madrid, Spain

  Disclosure: Biomerieux (Research Grant or Support)

Presenting Author(s)

• 

  Sarah Bandy, B.S.

  PharmD candidate
  University of Texas at Austin College of Pharmacy
  San Antonio, TX

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

  Slides Slides and Audio
• 

  Ana Halperin, MD

  Clinical Microbiologist, Chief Resident
  Clinical Microbiology
  Hospital Ramón y Cajal
  Madrid, Madrid, Spain

  Disclosure: Biomérieux (Grant/Research Support)

  Slides Slides and Audio
• 

  Ayesha Khan, PhD

  Postdoctoral Fellow in Infectious Diseases
  Center for Antimicrobial Resistance and Microbial Genomics (CARMiG)
  UTHealth
  Houston, TX

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

  Slides Slides and Audio
• 

  Maxwell Lasko, PharmD

  Infectious Disease Pharmacy Fellow
  Center for Anti Infective Research and Development
  Hartford, Connecticut

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

  Slides Slides and Audio
• 

  Alexander Lawandi, MD

  Fellow
  Department of Critical Care Medicine, National Institutes of Health Clinical Center
  Bethesda, Maryland

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

  Slides Slides and Audio

Presentations:

• evaluation of Synergy Testing Methods for Clinical Labs to Determine Susceptibility of Extensively Drug-resistant Gram-negatives to Ceftazidime/ Avibactam and Aztreonam Combination Therapy
  Ayesha Khan, PhD – UTHealth; Samuel G. Erickson, BS – McGovern Medical School; Cedric H. Pettaway, Jr., BS – McGovern Medical School; Cesar A. Arias, M.D., MSc, Ph.D., FIDSA – CARMiG, UTHealth and Center for Infectious Diseases, UTHealth School of Public Health, HOU, TX ; Molecular Genetics and Antimicrobial Resistance Unit and International Center for Microbial Genomics, Universidad El Bosque, BOG, COL; William R. Miller, MD – UTHealth McGovern Medical School; Micah M. Bhatti, MD, PhD – The University of Texas MD Anderson Cancer Center
• The Impact of the Verigene® Gram-positive Blood Culture Panel on the Management of Vancomycin Resistant enterococci Bloodstream Infections in a Multi-site Cohort Study
  Christopher Jackson, PharmD – University of Texas at Austin College of Pharmacy; Sarah Bandy, B.S. – University of Texas at Austin College of Pharmacy; Will Godinez, B.S., PharmD – University of Texas at Austin College of Pharmacy; Gerard Gawrys, PharmD, BCPS, BCIDP – Methodist Hospital & Methodist Children's Hospital; Grace Lee, PharmD, PhD, BCPS – The University of Texas at Austin College of Pharmacy, Pharmacotherapy Education and Research Center, School of Medicine, UT Health San Antonio
• Evaluation of the Bact/alert® VIRTUO™ in Terms of Time to Detection, Performance, Workflow Efficiency and Impact on Patient Management, Compared to the BACTEC™ FX Automated Blood Culture System
  Ana V. Halperin, MD – Hospital Ramón y Cajal; José Luis Cortés Cuevas, MD – Hospital Ramón y Cajal; Juan Antonio Del Castillo Polo, MD – Hospital Ramón y Cajal; Miriam Cuesta, n/a – Hospital Ramón y Cajal; Sergio Talens, n/a – Hospital Ramón y Cajal; Robert Birch, n/a – Biomérieux; Ana María Sánchez Díaz, PharmD. PhD. – Hospital Ramón y Cajal; Rafael Cantón, PharmD PhD – Hospital Ramón y Cajal
• Evaluation of Rapid Phenotypic Testing for KPC Carbapenemase Producing klebsiella Pneumoniae Directly from Positive Blood Cultures by Use of "Hot Chocolate" Plates
  Alexander Lawandi, MD – Department of Critical Care Medicine, National Institutes of Health Clinical Center; Gleice C. Leite, PhD – McGill University Health Centre; Brigitte Lefebvre, PhD – Institut National de Santé Publique du Québec; Jean Longtin, MD – Université Laval; Todd C. Lee, MD, MPH – McGill University
• Evaluation of Etest for Antibiotic Susceptibility and Minimum Inhibitory Concentration (MIC) Agreement Against pseudomonas Aeruginosa (psa) from Patients with Cystic Fibrosis (CF)
  Maxwell J. Lasko, PharmD – Center for Anti Infective Research and Development; Holly Huse, PhD. D(ABMM) – Huntington Hospital; Joseph L. Kuti, PharmD – Center for Anti-Infective Research and Development, Hartford Hospital; David P. Nicolau, PharmD – Hartford Hospital